Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) approved for marketing in second indication by NMPA for...

Zai Lab announces acceptance of biologics license application for TIVDAK for the treatment of patients...

ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and...

WuXi XDC and AbTis announce strategic partnership to advance next-generation ADCs

Immunome doses first patient in Phase 1 trial of IM-1021, a ROR1-targeted ADC